Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juli 2022

Genmab — Juli 2022

Planlagt Fastgjort Låst Flyttet Genmab
808 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • L Offline
    L Offline
    lahn1
    wrote on sidst redigeret af
    #685

    Hvem er ham James Bond med butterfly på forsiden ? 😉

    1 Reply Last reply
    0
    • Helge_LarsenPI-redaktørH Offline
      Helge_LarsenPI-redaktørH Offline
      Helge_LarsenPI-redaktør
      wrote on sidst redigeret af
      #686

      Godmorgen. 🙂

      1 Reply Last reply
      0
      • Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktør
        wrote on sidst redigeret af
        #687

        lahn...Jeg er klædt på til lejligheden. Det er altid en fest at være på PI. 🙂

        1 Reply Last reply
        0
        • S Offline
          S Offline
          Stroka
          wrote on sidst redigeret af
          #688

          God morgen. 🙂

          1 Reply Last reply
          0
          • P Offline
            P Offline
            ProinvestorNEWS
            wrote on sidst redigeret af
            #689

            Genmab/BMO: Hæver kursmålet med over 100 kr.
            https://www.proinvestor.com/investornyt/855348/genmab-bmo-haever-kursmalet-med-over-100-kr

            1 Reply Last reply
            0
            • J Offline
              J Offline
              JKY_VH
              wrote on sidst redigeret af
              #690

              Tak for den og god morgen;-)

              1 Reply Last reply
              0
              • B Offline
                B Offline
                bibob
                wrote on sidst redigeret af
                #691

                God morgen. 🙂

                1 Reply Last reply
                0
                • B Offline
                  B Offline
                  bibob
                  wrote on sidst redigeret af
                  #692

                  https://www.onclive.com/view/teclistamab-approaches-eu-approval-for-relapsed-refractory-multiple-myeloma?utm_source=sfmc&utm_medium=email&utm_campaign=07252022_OncLive_SAN-22-OSD1317_MM CC_Sanofi_Sarclisa_GLOBAL&eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==
                  Teclistamab.

                  1 Reply Last reply
                  0
                  • D Offline
                    D Offline
                    Doublo
                    wrote on sidst redigeret af
                    #693

                    Godmorgen:-) mon ikke den "generøse" kursforhøjelse fra BMO er et forsøg på at holde kursen nede, sjovt at man kan bruge en kursforhøjelse til det.

                    1 Reply Last reply
                    0
                    • R Offline
                      R Offline
                      Riis7
                      wrote on sidst redigeret af
                      #694

                      Godmorgen, Mon ikke 2500-2600 er fair value på Genmab indtil der kommer nyt for pipeline eller bedre salg på dara 🙂 vi er lige steget fra 1875 til 2600:-) market er stadig meget nervøs med Putins magt over gas/olie . de har os stadig tabt en voldgiftsag på deres bedst sælgende produkt.

                      1 Reply Last reply
                      0
                      • P Offline
                        P Offline
                        peter12
                        wrote on sidst redigeret af
                        #695

                        Ny artikel om HexElect https://www.nature.com/articles/s41587-022-01384-1

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #696

                          I wonder if we can deduce from that , that they are actively working on a CD52/CD20 combination

                          1 Reply Last reply
                          0
                          • P Offline
                            P Offline
                            peter12
                            wrote on sidst redigeret af
                            #697

                            They
                            mention CLL several times in the article

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #698

                              would be nice if we could see some interest in the Hexelect platform with a deal at some point... we are also still waiting for BionTech to say anything about the HexaBody product they are probably working on...

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #699

                                Btw, another Nature article this month- Changing the face of thyroid eye disease https://www.nature.com/articles/s41433-022-02186-0

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sukkeralf
                                  wrote on sidst redigeret af
                                  #700

                                  Just a moment...

                                  favicon

                                  (firstwordpharma.com)

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #701

                                    Maybe a competitor for Horizon at a later stage in TED

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #702

                                      Janssen Announces New Data Supporting Safety and Efficacy of RYBREVANT® and Lazertinib Combination for Patients with Non-Small Cell Lung Cancer and EGFR Mutations https://www.prnewswire.com/news-releases/janssen-announces-new-data-supporting-safety-and-efficacy-of-rybrevant-and-lazertinib-combination-for-patients-with-non-small-cell-lung-cancer-and-egfr-mutations-301593280.html

                                      1 Reply Last reply
                                      0
                                      • D Offline
                                        D Offline
                                        deleted-user
                                        wrote on sidst redigeret af
                                        #703

                                        Hvad hjælper det JnJ sender en PR kl. 15.29, når E L har breaket 14:53.....

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #704

                                          haha really? maybe they want us to proof-read it first 😉

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper